Eveline Kersten1, Maartje J Geerlings1, Anneke I den Hollander1,2, Eiko K de Jong1, Sascha Fauser3, Tunde Peto4, Carel B Hoyng1. 1. Department of Ophthalmology, Donders Institute for Brain, Cognition, and Behaviour, Radboud University Medical Center, Nijmegen, the Netherlands. 2. Department of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands. 3. Department of Ophthalmology, University Hospital of Cologne, Cologne, Germany. 4. Centre for Public Health, School of Medicine, Dentistry and Biomedical Science, Queen's University Belfast, Northern Ireland, United Kingdom.
Abstract
Importance: Rare variants in the complement factor H (CFH) gene and their association with age-related macular degeneration (AMD) have been described. However, there is limited literature on the phenotypes accompanying these rare variants. Phenotypical characteristics could help ophthalmologists select patients for additional genetic testing. Objective: To describe the phenotypical characteristics of patients with AMD carrying a rare variant in the CFH gene. Design, Setting, and Participants: In this cross-sectional study, we searched the genetic database of the department of ophthalmology at the Radboudumc (tertiary ophthalmologic referral center) and the European Genetic Database for patients with AMD with a rare genetic variant in the CFH gene. Patient recruitment took place from March 30, 2006, to February 18, 2013, and data were analyzed from November 30, 2015, to May 8, 2017. Phenotypical features on fundus photographs of both eyes of patients were graded by 2 independent reading center graders masked for carrier status. Main Outcomes and Measures: Differences in phenotypical characteristics between rare variant carriers and noncarriers were analyzed using univariable generalized estimated equations logistic regression models accounting for intereye correlation. Results: Analyses included 100 eyes of 51 patients with AMD carrying a CFH variant (mean [SD] age, 66.7 [12.1] years; 64.7% female) and 204 eyes of 102 age-matched noncarriers (mean [SD] age, 67.1 [11.8] years; 54.9% female). Carrying a rare pathogenic CFH variant was associated with larger drusen area (odds ratio range, 6.98 [95% CI, 2.04-23.89] to 18.50 [95% CI, 2.19-155.99]; P = .002), presence of drusen with crystalline appearance (odds ratio, 3.24; 95% CI, 1.24-8.50; P = .02), and drusen nasal to the optic disc (odds ratio range, 4.03 [95% CI, 1.70-9.56] to 7.42 [95% CI, 0.65-84.84]; P = .003). Conclusions and Relevance: Identification of rare CFH variant carriers may be important for upcoming complement-inhibiting therapies. Patients with an extensive drusen area, drusen with crystalline appearance, and drusen nasal to the optic disc are more likely to have a rare variant in the CFH gene. However, it is not likely that carriers can be discriminated from noncarriers based solely on phenotypical characteristics from color fundus images. Therefore, ophthalmologists should consider genetic testing in patients with these phenotypic characteristics in combination with other patient characteristics, such as early onset, cuticular drusen on fluorescein angiography, and family history of AMD.
Importance: Rare variants in the complement factor H (CFH) gene and their association with age-related macular degeneration (AMD) have been described. However, there is limited literature on the phenotypes accompanying these rare variants. Phenotypical characteristics could help ophthalmologists select patients for additional genetic testing. Objective: To describe the phenotypical characteristics of patients with AMD carrying a rare variant in the CFH gene. Design, Setting, and Participants: In this cross-sectional study, we searched the genetic database of the department of ophthalmology at the Radboudumc (tertiary ophthalmologic referral center) and the European Genetic Database for patients with AMD with a rare genetic variant in the CFH gene. Patient recruitment took place from March 30, 2006, to February 18, 2013, and data were analyzed from November 30, 2015, to May 8, 2017. Phenotypical features on fundus photographs of both eyes of patients were graded by 2 independent reading center graders masked for carrier status. Main Outcomes and Measures: Differences in phenotypical characteristics between rare variant carriers and noncarriers were analyzed using univariable generalized estimated equations logistic regression models accounting for intereye correlation. Results: Analyses included 100 eyes of 51 patients with AMD carrying a CFH variant (mean [SD] age, 66.7 [12.1] years; 64.7% female) and 204 eyes of 102 age-matched noncarriers (mean [SD] age, 67.1 [11.8] years; 54.9% female). Carrying a rare pathogenic CFH variant was associated with larger drusen area (odds ratio range, 6.98 [95% CI, 2.04-23.89] to 18.50 [95% CI, 2.19-155.99]; P = .002), presence of drusen with crystalline appearance (odds ratio, 3.24; 95% CI, 1.24-8.50; P = .02), and drusen nasal to the optic disc (odds ratio range, 4.03 [95% CI, 1.70-9.56] to 7.42 [95% CI, 0.65-84.84]; P = .003). Conclusions and Relevance: Identification of rare CFH variant carriers may be important for upcoming complement-inhibiting therapies. Patients with an extensive drusen area, drusen with crystalline appearance, and drusen nasal to the optic disc are more likely to have a rare variant in the CFH gene. However, it is not likely that carriers can be discriminated from noncarriers based solely on phenotypical characteristics from color fundus images. Therefore, ophthalmologists should consider genetic testing in patients with these phenotypic characteristics in combination with other patient characteristics, such as early onset, cuticular drusen on fluorescein angiography, and family history of AMD.
Authors: Michael P Triebwasser; Elisha D O Roberson; Yi Yu; Elizabeth C Schramm; Erin K Wagner; Soumya Raychaudhuri; Johanna M Seddon; John P Atkinson Journal: Invest Ophthalmol Vis Sci Date: 2015-10 Impact factor: 4.799
Authors: Yi Yu; Michael P Triebwasser; Edwin K S Wong; Elizabeth C Schramm; Brett Thomas; Robyn Reynolds; Elaine R Mardis; John P Atkinson; Mark Daly; Soumya Raychaudhuri; David Kavanagh; Johanna M Seddon Journal: Hum Mol Genet Date: 2014-05-20 Impact factor: 6.150
Authors: Usha Chakravarthy; Tien Y Wong; Astrid Fletcher; Elisabeth Piault; Christopher Evans; Gergana Zlateva; Ronald Buggage; Andreas Pleil; Paul Mitchell Journal: BMC Ophthalmol Date: 2010-12-13 Impact factor: 2.209
Authors: Maheswara R Duvvari; Nicole T M Saksens; Johannes P H van de Ven; Yvonne de Jong-Hesse; Tina Schick; Willy M Nillesen; Sascha Fauser; Lies H Hoefsloot; Carel B Hoyng; Eiko K de Jong; Anneke I den Hollander Journal: Mol Vis Date: 2015-03-15 Impact factor: 2.367
Authors: Nicole T M Saksens; Yara T E Lechanteur; Sanne K Verbakel; Joannes M M Groenewoud; Mohamed R Daha; Tina Schick; Sascha Fauser; Camiel J F Boon; Carel B Hoyng; Anneke I den Hollander Journal: PLoS One Date: 2016-06-03 Impact factor: 3.240
Authors: Alexandra Pietraszkiewicz; Freekje van Asten; Alan Kwong; Rinki Ratnapriya; Goncalo Abecasis; Anand Swaroop; Emily Y Chew Journal: Ophthalmology Date: 2017-12-08 Impact factor: 12.079
Authors: Sarah de Jong; Anita de Breuk; Elena B Volokhina; Bjorn Bakker; Alejandro Garanto; Sascha Fauser; Suresh Katti; Carel B Hoyng; Yara T E Lechanteur; Lambert P van den Heuvel; Anneke I den Hollander Journal: Hum Mol Genet Date: 2022-02-03 Impact factor: 6.150
Authors: Thomas J Heesterbeek; Laura Lorés-Motta; Carel B Hoyng; Yara T E Lechanteur; Anneke I den Hollander Journal: Ophthalmic Physiol Opt Date: 2020-02-25 Impact factor: 3.117
Authors: Andrea R Waksmunski; Kristy Miskimen; Yeunjoo E Song; Michelle Grunin; Renee Laux; Denise Fuzzell; Sarada Fuzzell; Larry D Adams; Laura Caywood; Michael Prough; Dwight Stambolian; William K Scott; Margaret A Pericak-Vance; Jonathan L Haines Journal: Invest Ophthalmol Vis Sci Date: 2022-08-02 Impact factor: 4.925
Authors: Anita de Breuk; Yara T E Lechanteur; Thomas J Heesterbeek; Sascha Fauser; Caroline C W Klaver; Carel B Hoyng; Anneke I den Hollander Journal: Ophthalmol Sci Date: 2021-12-06
Authors: Rinki Ratnapriya; İlhan E Acar; Maartje J Geerlings; Kari Branham; Alan Kwong; Nicole T M Saksens; Marc Pauper; Jordi Corominas; Madeline Kwicklis; David Zipprer; Margaret R Starostik; Mohammad Othman; Beverly Yashar; Goncalo R Abecasis; Emily Y Chew; Deborah A Ferrington; Carel B Hoyng; Anand Swaroop; Anneke I den Hollander Journal: Hum Mol Genet Date: 2020-07-29 Impact factor: 6.150